Home › Trial NCT04901299
Fulvestrant + Neratinib In Breast Cancer
- Trial IDNCT04901299
- StatusWithdrawn
- PhasePhase 2
- Study typeInterventional
- SponsorMassachusetts General Hospital
- Enrollment—
- Start date2023-07
- ConditionsStage IV (Metastatic) Breast Cancer · Metastatic Breast Cancer · ER Positive Breast Cancer · PR-Positive Breast Cancer · HER2-negative Breast Cancer · Invasive Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.